Qiuyu Meng1, Zhifu Cen2. 1. Department of Thyroid Surgery, West China Hospital, Sichuan University, No. 37, Guoxue Alley, 610041, Chengdu, Sichuan, China. 2. Department of Cardiology, West China Hospital, Sichuan University, No. 37, Guoxue Alley, 610041, Chengdu, Sichuan, China. cen_zhifu@163.com.
Abstract
BACKGROUND: New oral anticoagulants (NOACs) are as effective and safe as warfarin for patients with non-valvular atrial fibrillation (NVAF). Limited evidence is available regarding outcomes for NVAF patients with peripheral artery disease (PAD). METHODS: A systematic search of Medline, Embase, and the Cochrane Library was performed. Two reviewers independently performed data extraction and quality assessment using the Cochrane Collaboration tool for assessing risk of bias. All primary publications and secondary analyses comparing NOACs with other oral anticoagulation regimens for the prevention of stroke in patients with both NVAF and PAD from phase III clinical trials were evaluated. The primary outcomes were stroke, systemic embolism (SE), major bleeding, and intracranial hemorrhage (ICH), and the secondary outcomes were cardiovascular (CV) mortality, all-cause mortality, and myocardial infarction (MI). RESULTS: Three articles were included in this study. The pooled results showed a relative risk for stroke/SE with NOACs of 0.86 (95% confidence interval [CI]: 0.53-1.39), for major bleeding, 1.12 (95% CI: 0.70-1.81), for ICH, 0.47 (95% CI: 0.16-1.36), for CV mortality, 0.77 (95% CI: 0.57-1.04), for all-cause mortality, 0.91 (95% CI: 0.70-1.19), and for MI, 1.10 (95% CI: 0.64-1.90). CONCLUSION: The findings show that NOACs are effective and safe for preventing stroke/SE in patients with both NVAF and PAD.
BACKGROUND: New oral anticoagulants (NOACs) are as effective and safe as warfarin for patients with non-valvular atrial fibrillation (NVAF). Limited evidence is available regarding outcomes for NVAF patients with peripheral artery disease (PAD). METHODS: A systematic search of Medline, Embase, and the Cochrane Library was performed. Two reviewers independently performed data extraction and quality assessment using the Cochrane Collaboration tool for assessing risk of bias. All primary publications and secondary analyses comparing NOACs with other oral anticoagulation regimens for the prevention of stroke in patients with both NVAF and PAD from phase III clinical trials were evaluated. The primary outcomes were stroke, systemic embolism (SE), major bleeding, and intracranial hemorrhage (ICH), and the secondary outcomes were cardiovascular (CV) mortality, all-cause mortality, and myocardial infarction (MI). RESULTS: Three articles were included in this study. The pooled results showed a relative risk for stroke/SE with NOACs of 0.86 (95% confidence interval [CI]: 0.53-1.39), for major bleeding, 1.12 (95% CI: 0.70-1.81), for ICH, 0.47 (95% CI: 0.16-1.36), for CV mortality, 0.77 (95% CI: 0.57-1.04), for all-cause mortality, 0.91 (95% CI: 0.70-1.19), and for MI, 1.10 (95% CI: 0.64-1.90). CONCLUSION: The findings show that NOACs are effective and safe for preventing stroke/SE in patients with both NVAF and PAD.
Authors: Stefan H Hohnloser; Jonas Oldgren; Sean Yang; Lars Wallentin; Michael Ezekowitz; Paul Reilly; John Eikelboom; Martina Brueckmann; Salim Yusuf; Stuart J Connolly Journal: Circulation Date: 2012-01-03 Impact factor: 29.690
Authors: Renato D Lopes; Jan Steffel; Manuela Di Fusco; Allison Keshishian; Xuemei Luo; Xiaoyan Li; Cristina Masseria; Melissa Hamilton; Keith Friend; Kiran Gupta; Jack Mardekian; Xianying Pan; Onur Baser; W Schuyler Jones Journal: Am J Med Date: 2018-05-26 Impact factor: 4.965
Authors: Jan Steffel; Peter Verhamme; Tatjana S Potpara; Pierre Albaladejo; Matthias Antz; Lien Desteghe; Karl Georg Haeusler; Jonas Oldgren; Holger Reinecke; Vanessa Roldan-Schilling; Nigel Rowell; Peter Sinnaeve; Ronan Collins; A John Camm; Hein Heidbüchel Journal: Eur Heart J Date: 2018-04-21 Impact factor: 29.983
Authors: William Schuyler Jones; Anne S Hellkamp; Jonathan Halperin; Jonathan P Piccini; Gunter Breithardt; Daniel E Singer; Keith A A Fox; Graeme J Hankey; Kenneth W Mahaffey; Robert M Califf; Manesh R Patel Journal: Eur Heart J Date: 2013-12-02 Impact factor: 29.983
Authors: Peter T Hu; Renato D Lopes; Susanna R Stevens; Lars Wallentin; Laine Thomas; John H Alexander; Michael Hanna; Basil S Lewis; Freek W A Verheugt; Christopher B Granger; W Schuyler Jones Journal: J Am Heart Assoc Date: 2017-01-17 Impact factor: 5.501
Authors: Mark J Alberts; Deepak L Bhatt; Jean-Louis Mas; E Magnus Ohman; Alan T Hirsch; Joachim Röther; Geneviève Salette; Shinya Goto; Sidney C Smith; Chiau-Suong Liau; Peter W F Wilson; Ph Gabriel Steg Journal: Eur Heart J Date: 2009-08-31 Impact factor: 29.983